Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Chromosomal Abnormalities in Offspring of Young Cancer Survivors: A Population-Based Cohort Study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. HPV types, cervical high-grade lesions and risk factors for oncogenic human papillomavirus infection among 3416 Tanzanian women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Xin Yang
  • Honglin Song
  • Goska Leslie
  • Christoph Engel
  • Eric Hahnen
  • Bernd Auber
  • Judit Horváth
  • Karin Kast
  • Dieter Niederacher
  • Clare Turnbull
  • Richard Houlston
  • Helen Hanson
  • Chey Loveday
  • Jill S Dolinsky
  • Holly LaDuca
  • Susan J Ramus
  • Usha Menon
  • Adam N Rosenthal
  • Ian Jacobs
  • Simon A Gayther
  • Ed Dicks
  • Heli Nevanlinna
  • Kristiina Aittomäki
  • Liisa M Pelttari
  • Hans Ehrencrona
  • Åke Borg
  • Anders Kvist
  • Barbara Rivera
  • Thomas V O Hansen
  • Malene Djursby
  • Andrew Lee
  • Joe Dennis
  • David D Bowtell
  • Nadia Traficante
  • Orland Diez
  • Judith Balmaña
  • Stephen B Gruber
  • Georgia Chenevix-Trench
  • kConFab Investigators
  • Allan Jensen
  • Susanne K Kjær
  • Estrid Høgdall
  • Laurent Castéra
  • Judy Garber
  • Ramunas Janavicius
  • Ana Osorio
  • Lisa Golmard
  • Ana Vega
  • Fergus J Couch
  • Mark Robson
  • Jacek Gronwald
  • Susan M Domchek
  • Julie O Culver
  • Miguel de la Hoya
  • Douglas F Easton
  • William D Foulkes
  • Marc Tischkowitz
  • Alfons Meindl
  • Rita K Schmutzler
  • Paul D P Pharoah
  • Antonis C Antoniou
Vis graf over relationer

BACKGROUND: The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C and RAD51D.

METHODS: We analyzed data from 6178 families, 125 with pathogenic variants in RAD51C, and 6690 families, 60 with pathogenic variants in RAD51D. TOC and BC relative and cumulative risks were estimated using complex segregation analysis to model the cancer inheritance patterns in families while adjusting for the mode of ascertainment of each family. All statistical tests were two-sided.

RESULTS: Pathogenic variants in both RAD51C and RAD51D were associated with TOC (RAD51C: relative risk [RR] = 7.55, 95% confidence interval [CI] = 5.60 to 10.19; P = 5 × 10-40; RAD51D: RR = 7.60, 95% CI = 5.61 to 10.30; P = 5 × 10-39) and BC (RAD51C: RR = 1.99, 95% CI = 1.39 to 2.85; P = 1.55 × 10-4; RAD51D: RR = 1.83, 95% CI = 1.24 to 2.72; P = .002). For both RAD51C and RAD51D, there was a suggestion that the TOC relative risks increased with age until around age 60 years and decreased thereafter. The estimated cumulative risks of developing TOC to age 80 years were 11% (95% CI = 6% to 21%) for RAD51C and 13% (95% CI = 7% to 23%) for RAD51D pathogenic variant carriers. The estimated cumulative risks of developing BC to 80 years were 21% (95% CI = 15% to 29%) for RAD51C and 20% (95% CI = 14% to 28%) for RAD51D pathogenic variant carriers. Both TOC and BC risks for RAD51C and RAD51D pathogenic variant carriers varied by cancer family history and could be as high as 32-36% for TOC, for carriers with two first-degree relatives diagnosed with TOC, or 44-46% for BC, for carriers with two first-degree relatives diagnosed with BC.

CONCLUSIONS: These estimates will facilitate the genetic counseling of RAD51C and RAD51D pathogenic variant carriers and justify the incorporation of RAD51C and RAD51D into cancer risk prediction models.

OriginalsprogEngelsk
TidsskriftNational Cancer Institute. Journal (Online)
Vol/bind112
Udgave nummer12
Sider (fra-til)1242-1250
Antal sider9
ISSN1460-2105
DOI
StatusUdgivet - 14 dec. 2020

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press.

ID: 61713776